Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis

Nephrology Dialysis Transplantation

Volumn 27, Issue 10, 2012, Pages 3823-3828

  Hutchison, Colin A ^a   Heyne, Nils ^b   Airia, Parisa ^c   Schindler, Ralf ^d   Zickler, Daniel ^d   Cook, Mark ^a   Cockwell, Paul ^a   Grima, Daniel ^c  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c Department of Data Analytics and Evidence Synthesis   (Canada)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

acute renal failure; free light chains; high cut off haemodialysis; multiple myeloma; myeloma kidney

Indexed keywords

BORTEZOMIB; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; PREDNISONE; THALIDOMIDE;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CREATININE BLOOD LEVEL; FEMALE; HEMODIALYSIS; HIGH CUT OFF HEMODIALYSIS; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; KIDNEY BIOPSY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION;

ACUTE KIDNEY INJURY; AGED; BORONIC ACIDS; COMBINED MODALITY THERAPY; DATABASES, FACTUAL; DEXAMETHASONE; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RENAL DIALYSIS; THALIDOMIDE;

EID: 84865433133     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr773     Document Type: Article

References (16)

1. Sanders PW, Booker BB. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 1992; 89: 630-639
2. Haynes RJ, Read S, Collins GP et al. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: 20-year experience from a single centre. Nephrol Dial Transplant 2010; 25: 419-426
3. Leung N, Gertz MA, Zeldenrust SR et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008; 73: 1282-1288
4. Hutchison CA, Cockwell P, Stringer S et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 2011; 22: 1129-1136
5. Hutchison CA, Cockwell P, Reid S et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007; 18: 886-895
6. Bachmann U, Schindler R, Storr M et al. Combination of bortezomibbased chemotherapy and extracorporeal free light chain removal for treating cast nephropathy in multiple myeloma. NDT Plus 2008; 1: 106-108
7. Hutchison CA, Bradwell AR, Cook M et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009; 4: 745-754
8. Hutchison CA, Cook M, Heyne N et al. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials 2008; 9: 55
9. Blade J, Fernandez-Llama P, Bosch F et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889-1893
10. Hutchison CA, Harding S, Mead G et al. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs 2008; 32: 910-917
11. Kastritis E, Anagnostopoulos A, Roussou M et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 2007; 92: 546-549
12. Ludwig H, Drach J, Graf H et al. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 2007; 92: 1411-1414
13. Ludwig H, Adam Z, Hajek R et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 2010; 28: 4635-4641
14. Dimopoulos MA, Roussou M, Gavriatopoulou M et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma 2009; 9: 302-306
15. Hutchison CA, Harding S, Hewins P et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1684-1690
16. Roussou M, Kastritis E, Chrostoulas D et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 2010; 34: 1395-1397